Hims & Hers Health, Inc

Hims & Hers Health, Inc. (NYSE: HIMS) provides a consumer-focused digital platform that addresses diverse health and wellness requirements. The platform includes access to licensed healthcare professionals, a clinically oriented electronic health records system, digital prescription capabilities, cloud-enabled pharmacy services, and sophisticated tools for personalized care delivery.

Key Business Updates for Q2FY25

• Strong Revenue Growth and Subscriber Expansion in Q2 2025: Hims & Hers Health, Inc. (NYSE: HIMS), a prominent digital health and wellness platform, reported a significant year-over-year revenue increase of 73% for the second quarter of 2025, reaching USD 544.8 million, up from USD 315.6 million in Q2 2024. This growth was driven by continued demand for personalized healthcare solutions. The company also reported an increase in total subscribers to approximately 2.44 million, representing a 31% rise compared to the prior-year quarter.
• Profitability and Operating Performance: In terms of profitability, Hims & Hers posted a net income of USD 42.5 million for the quarter, a notable improvement from USD 13.3 million reported in the same period last year. Adjusted EBITDA more than doubled year-over-year, reaching USD 82.2 million compared to USD 39.3 million in Q2 2024. However, despite profitability at the net income and EBITDA levels, the company experienced negative cash flow trends, with net cash used in operating activities totaling USD (19.1) million and free cash flow at USD (69.4) million for the quarter.
• Revenue Composition and Margins: The vast majority of revenue was derived from online sales, which totaled USD 536.9 million, marking a 75% increase from the prior year. Wholesale revenue, however, declined by 10% to USD 8.0 million. Overall gross margin for the quarter declined to 76%, compared to 81% in Q2 2024, suggesting a shift in cost structure or product mix despite the higher revenue base.
• Improvement in Customer Economics: Customer engagement and monetization continued to improve, as reflected by a 30% year-over-year increase in monthly online revenue per average subscriber to USD 74 in Q2 2025. For the six-month period ended June 30, 2025, this figure rose even further to USD 79, indicating growing demand for comprehensive and personalized treatment plans offered by the company.
• Executive Commentary and Strategic Outlook: CEO Andrew Dudum emphasized the company’s role in transforming the healthcare landscape by providing high-quality, personalized care at scale. He noted that Hims & Hers is entering an inflection point of growth, with plans to expand into new specialties that could significantly broaden its reach and impact. The long-term strategy involves shifting from single-issue solutions to a comprehensive health management platform.
• Investment in Platform Capabilities and International Expansion: Chief Financial Officer Yemi Okupe highlighted consistent growth across core business areas, attributing performance to increasing adoption of precision care. As part of the forward strategy, the company intends to deepen platform capabilities by enhancing personalization in pharmacy operations, expanding lab testing offerings, and scaling its international footprint in key markets.
• Forward Guidance and Financial Outlook for 2025: For the third quarter of 2025, Hims & Hers projects revenue between USD 570 million and USD 590 million, with an expected Adjusted EBITDA of USD 60 million to USD 70 million, translating to an EBITDA margin of 11% to 12%. Full-year 2025 guidance remains unchanged, with anticipated revenue in the range of USD 2.3 billion to USD 2.4 billion and Adjusted EBITDA between USD 295 million and USD 335 million. The company noted that these forecasts are subject to market conditions and uncertainties, and certain reconciliations to U.S. GAAP metrics remain unavailable due to the inherent unpredictability of market-driven variables.

Technical Commentary:

Hims & Hers Health, Inc. (HIMS) experienced a sharp 8.23% drop on high volume, indicating potential short-term weakness despite maintaining its broader uptrend. The stock remains above its 21-day and 50-day moving averages, suggesting medium-term bullish momentum is intact. However, the RSI has cooled to 53.38, reflecting fading strength.

As per the above-mentioned price action, recent key business and financial updates, momentum in the stock over the last month, and technical indicators analysis, a ‘Watch’ rating has been given to Hims & Hers Health, Inc (NYSE: HIMS) at the current market price of USD 58.13 as of August 05, 2025, at 9:10 am PDT. 

Individuals can evaluate the stock based on the support and resistance levels provided in the report in case of keen interest taking into consideration the risk-reward scenario. 

Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.

Related Risk: This report may be looked at from a high-risk perspective and a recommendation is provided for a short duration. This report is solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc.

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is August 05, 2025. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level that the stock is expected to reach as per the relative valuation method and or technical analysis taking into consideration both short-term and long-term scenarios.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.